Literature DB >> 12937004

Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis.

Annika Krüüner1, Pontus Jureen, Klavdia Levina, Solomon Ghebremichael, Sven Hoffner.   

Abstract

It is generally thought that there is full cross-resistance in Mycobacterium tuberculosis between the aminoglycoside drugs kanamycin and amikacin. However, kanamycin resistance and amikacin susceptibility were seen in 43 of 79 (54%) multidrug-resistant Estonian isolates, indicating that there might be a need to test the resistance of M. tuberculosis isolates to both drugs.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12937004      PMCID： PMC182599          DOI： 10.1128/AAC.47.9.2971-2973.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

Review 2.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

3.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  M A Espinal; A Laszlo; L Simonsen; F Boulahbal; S J Kim; A Reniero; S Hoffner; H L Rieder; N Binkin; C Dye; R Williams; M C Raviglione
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

4.  Interaction of antibiotics with functional sites in 16S ribosomal RNA.

Authors:  D Moazed; H F Noller
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

5.  In vitro and in vivo laboratory studies on the antituberculous activity of capreomycin.

Authors:  W B Sutton; R S Gordee; W E Wick; L Stanfield
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

6.  Sequence polymorphism in the rrs gene of Mycobacterium tuberculosis is deeply rooted within an evolutionary clade and is not associated with streptomycin resistance.

Authors:  T C Victor; A van Rie; A M Jordaan; M Richardson; G D van Der Spuy; N Beyers; P D van Helden; R Warren
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

7.  Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology.

Authors:  J D van Embden; M D Cave; J T Crawford; J W Dale; K D Eisenach; B Gicquel; P Hermans; C Martin; R McAdam; T M Shinnick
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

8.  Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis.

Authors:  M Tsukamura; S Mizuno
Journal:  J Gen Microbiol       Date:  1975-06

9.  Susceptibility of streptomycin-resistant Mycobacterium tuberculosis strains to amikacin.

Authors:  S E Hoffner; G Källenius
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

10.  Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin.

Authors:  J K McClatchy; W Kanes; P T Davidson; T S Moulding
Journal:  Tubercle       Date:  1977-03
View more
  23 in total

1.  Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study.

Authors:  Olga Ignatyeva; Irina Kontsevaya; Alexander Kovalyov; Yanina Balabanova; Vladislav Nikolayevskyy; Kadri Toit; Anda Dragan; Daniela Maxim; Svetlana Mironova; Tiina Kummik; Ionela Muntean; Ekaterina Koshkarova; Francis Drobniewski
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

2.  In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Authors:  J A Dijkstra; T van der Laan; O W Akkerman; M S Bolhuis; W C M de Lange; J G W Kosterink; T S van der Werf; J W C Alffenaar; D van Soolingen
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

3.  Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Authors:  Florence Brossier; Nicolas Veziris; Alexandra Aubry; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 4.  A balancing act: efflux/influx in mycobacterial drug resistance.

Authors:  G E Louw; R M Warren; N C Gey van Pittius; C R E McEvoy; P D Van Helden; T C Victor
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

5.  Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis.

Authors:  M Analise Zaunbrecher; R David Sikes; Beverly Metchock; Thomas M Shinnick; James E Posey
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

6.  Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.

Authors:  Florence Brossier; Anne Pham; Christine Bernard; Alexandra Aubry; Vincent Jarlier; Nicolas Veziris; Wladimir Sougakoff
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

Authors:  R van Altena; J A Dijkstra; M E van der Meer; J F Borjas Howard; J G W Kosterink; D van Soolingen; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.

Authors:  Courtney E Maus; Bonnie B Plikaytis; Thomas M Shinnick
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

9.  Molecular and phenotypic characterization of multidrug-resistant Mycobacterium tuberculosis isolates resistant to kanamycin, amikacin, and capreomycin in China.

Authors:  Z Zhang; M Liu; Y Wang; Y Pang; K M Kam; Y Zhao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-07       Impact factor: 3.267

Review 10.  Cure of tuberculosis using nanotechnology: An overview.

Authors:  Rout George Kerry; Sushanto Gouda; Bikram Sil; Gitishree Das; Han-Seung Shin; Gajanan Ghodake; Jayanta Kumar Patra
Journal:  J Microbiol       Date:  2018-05-02       Impact factor: 3.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.